Latest News about Geoff Meacham
Recent news which mentions Geoff Meacham
Eli Lilly's Upcoming Obesity Drugs Highlight Bright Future, Says Optimistic Analyst
October 06, 2023
Tickers
LLY
From Benzinga
Gilead Sciences Shares Trade Higher After Bullish Analyst Upgrades Stock
September 08, 2023
From Benzinga
Merck Vs. Pfizer: Why Analyst Upgrades One Pharmaceutical Stock, While Downgrading Another
January 04, 2023
From Benzinga
7 Biogen Analysts On Alzheimer's Drug Success As Stock Skyrockets 37%
September 28, 2022
Tickers
BIIB
From Benzinga
From Benzinga
From Benzinga
10 Investor Questions About COVID-19, Answered
April 03, 2022
From Benzinga
Ahead Of Moderna's Midstage mRNA Flu Vaccine Readout, Analyst Says Drugmaker Likely To Be First To Market
March 21, 2022
From Benzinga
Why This Analyst Has Increased Confidence In Inovio Pharmaceuticals
January 21, 2022
Tickers
INO
From Benzinga
BofA Bullish On This Gene Therapy Biotech Transitioning Into A Commercial Enterprise
January 18, 2022
Tickers
KRYS
From Benzinga
Why This Pfizer, Regeneron Analyst Has Contrasting Recommendations For The COVID Stock Plays
January 05, 2022
From Benzinga
How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?
December 23, 2021
From Benzinga
From Benzinga
From Benzinga
Merck's Oral COVID-19 Treatment Could Be Game-Changer: BofA Analyst
October 06, 2021
From Benzinga
Moderna Analysts Debate Need For Biopharma's COVID-19 Booster Shot
September 16, 2021
From Benzinga
From Benzinga
From Benzinga
Graphite Bio's Approach To Gene Editing Has BofA Securities and Morgan Stanley Bullish
July 20, 2021
From Benzinga
From Benzinga